{"DataElement":{"publicId":"6643831","version":"1","preferredName":"Acute Myeloid Leukemia Minimal Residual Disease Assay Specimen Quality Score 5 Point Scale","preferredDefinition":"An ordered reference standard used to measure incremental changes for representing the specimen quality 1: Bad quality, to 5: Best quality related to the acute myeloid leukemia minimal residual disease assay.","longName":"6643829v1.0:6643729v1.0","context":"Alliance","contextVersion":"1","DataElementConcept":{"publicId":"6643829","version":"1","preferredName":"Acute Myeloid Leukemia Minimal Residual Disease Assay Specimen Quality","preferredDefinition":"A clonal expansion of myeloid blasts in the bone marrow, blood or other tissues. The classification of acute myeloid leukemias (AMLs) encompasses four major categories: 1) AML with recurrent genetic abnormalities; 2) AML with multilineage dysplasia; 3) Therapy-related AML; 4) AML not otherwise specified. The required bone marrow or peripheral blood blast percentage for the diagnosis of AML is 20% (WHO classification)._Evidence for remaining tumor following primary treatment that is only apparent using highly sensitive techniques._A qualitative or quantitative analysis performed to determine the amount of a particular constituent in a sample or the biological or pharmacological potency of a drug._A part of a thing, or of several things, taken to demonstrate or to determine the character of the whole, e.g. a substance, or portion of material obtained for use in testing, examination, or study; particularly, a preparation of tissue or bodily fluid taken for examination or diagnosis._An essential and distinguishing attribute of something or someone; a degree or grade of excellence or worth.","longName":"2320063v1.0:6643827v1.0","context":"Alliance","contextVersion":"1","ObjectClass":{"publicId":"2320063","version":"1","preferredName":"Acute Myeloid Leukemia","preferredDefinition":"A clonal expansion of myeloid blasts in the bone marrow, blood or other tissues.  The classification of acute myeloid leukemias (AMLs) encompasses four major categories: 1) AML with recurrent genetic abnormalities 2) AML with multilineage dysplasia 3) Therapy-related AML 4) AML not otherwise categorized.  The required bone marrow or peripheral blood blast percentage for the diagnosis of AML has been recently reduced from 30% (French-American-British [FAB] classification) to 20% (WHO classification).  (WHO, 2001) -- 2003","longName":"C3171","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Acute Myeloid Leukemia","conceptCode":"C3171","definition":"A clonal expansion of myeloid blasts in the bone marrow, blood or other tissues. The classification of acute myeloid leukemias (AMLs) encompasses four major categories: 1) AML with recurrent genetic abnormalities; 2) AML with multilineage dysplasia; 3) Therapy-related AML; 4) AML not otherwise specified. The required bone marrow or peripheral blood blast percentage for the diagnosis of AML is 20% (WHO classification).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"FC71B93E-037A-5AD9-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-07-25","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-07-25","modifiedBy":"ONEDATA","dateModified":"2005-07-25","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"6643827","version":"1","preferredName":"Minimal Residual Disease Assay Specimen Quality","preferredDefinition":"Evidence for remaining tumor following primary treatment that is only apparent using highly sensitive techniques.:A qualitative or quantitative analysis performed to determine the amount of a particular constituent in a sample or the biological or pharmacological potency of a drug.:A part of a thing, or of several things, taken to demonstrate or to determine the character of the whole, e.g. a substance, or portion of material obtained for use in testing, examination, or study; particularly, a preparation of tissue or bodily fluid taken for examination or diagnosis.:An essential and distinguishing attribute of something or someone; a degree or grade of excellence or worth.","longName":"C3896:C60819:C19157:C25283","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Measurable Residual Disease","conceptCode":"C3896","definition":"Evidence for remaining tumor following primary treatment that is only apparent using highly sensitive techniques.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"3"},{"longName":"Assay","conceptCode":"C60819","definition":"A qualitative or quantitative analysis performed to determine the amount of a particular constituent in a sample or the biological or pharmacological properties of a drug.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Specimen","conceptCode":"C19157","definition":"A part of a thing, or of several things, taken to demonstrate or to determine the character of the whole, e.g. a substance, or portion of material obtained for use in testing, examination, or study; particularly, a preparation of tissue or bodily fluid taken for examination or diagnosis.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Quality","conceptCode":"C25283","definition":"An essential and distinguishing attribute of something or someone; a degree or grade of excellence or worth.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"81E1B5C6-B994-66D0-E053-F662850A7EBC","latestVersionIndicator":"Yes","beginDate":"2019-02-14","endDate":null,"createdBy":"MORENOC","dateCreated":"2019-02-14","modifiedBy":"ONEDATA","dateModified":"2019-02-14","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008547","version":"1","preferredName":"Specimen Characteristics","preferredDefinition":"attributes of a patient's laboratory sample, including the source, condition, and fixative.","longName":"SPEC_CHAR","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B22908C4-638F-4A74-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-19","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-19","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"Alliance Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"81E1B5C6-B9A5-66D0-E053-F662850A7EBC","latestVersionIndicator":"Yes","beginDate":"2019-02-14","endDate":null,"createdBy":"MORENOC","dateCreated":"2019-02-14","modifiedBy":"MORENOC","dateModified":"2019-11-06","changeDescription":"11/6/2019: CM Released as part of draft content review","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"6643729","version":"1","preferredName":"Specimen Quality Score 5 Point Scale","preferredDefinition":"An ordered reference standard used to measure incremental changes for representing the specimen quality 1: Bad quality, to 5: Best quality.","longName":"6643729v1.0","context":"Alliance","contextVersion":"1","type":"Enumerated","dataType":"NUMBER","minLength":"1","maxLength":"1","minValue":"1","maxValue":"5","decimalPlace":"0","PermissibleValues":[{"value":"1","valueDescription":"Bad","ValueMeaning":{"publicId":"6289670","version":"1","preferredName":"Bad","longName":"6289670","preferredDefinition":"Having undesirable or negative qualities.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Bad","conceptCode":"C80228","definition":"Having undesirable or negative qualities.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"6C5709EF-99B8-0B6D-E053-F662850AEA9C","latestVersionIndicator":"Yes","beginDate":"2018-05-16","endDate":null,"createdBy":"COOPERM","dateCreated":"2018-05-16","modifiedBy":"ONEDATA","dateModified":"2018-05-16","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"81E148E0-1CFE-5FC8-E053-F662850AA355","beginDate":"2019-02-14","endDate":null,"createdBy":"MORENOC","dateCreated":"2019-02-14","modifiedBy":"ONEDATA","dateModified":"2019-02-14","deletedIndicator":"No"},{"value":"2","valueDescription":"Poor","ValueMeaning":{"publicId":"3115746","version":"1","preferredName":"Poor","longName":"3115746","preferredDefinition":"Of low value or worth.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Poor","conceptCode":"C77959","definition":"Of low value or worth.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8A447119-04CA-8CC9-E040-BB89AD4332B2","latestVersionIndicator":"Yes","beginDate":"2010-06-30","endDate":null,"createdBy":"REEVESD","dateCreated":"2010-06-30","modifiedBy":"GDEEN","dateModified":"2023-12-20","changeDescription":null,"administrativeNotes":"2023.1.11 Alt VM Name added per ticket request CADSR0001837. ak","unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"81E148E0-1D08-5FC8-E053-F662850AA355","beginDate":"2019-02-14","endDate":null,"createdBy":"MORENOC","dateCreated":"2019-02-14","modifiedBy":"ONEDATA","dateModified":"2019-02-14","deletedIndicator":"No"},{"value":"3","valueDescription":"Hemodilution Specimen Quality","ValueMeaning":{"publicId":"6643730","version":"1","preferredName":"Hemodilution Specimen Quality","longName":"6643730","preferredDefinition":"Reduction of blood viscosity usually by the addition of cell free solutions. Used clinically (1) in states of impaired microcirculation, (2) for replacement of intraoperative blood loss without homologous blood transfusion, and (3) in cardiopulmonary bypass and hypothermia.: A part of a thing, or of several things, taken to demonstrate or to determine the character of the whole, e.g. a substance, or portion of material obtained for use in testing, examination, or study; particularly, a preparation of tissue or bodily fluid taken for examination or diagnosis.: An essential and distinguishing attribute of something or someone; a degree or grade of excellence or worth.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Hemodilution","conceptCode":"C0019009","definition":"Reduction of blood viscosity usually by the addition of cell free solutions. Used clinically (1) in states of impaired microcirculation, (2) for replacement of intraoperative blood loss without homologous blood transfusion, and (3) in cardiopulmonary bypass and hypothermia.","evsSource":"UMLS_CUI","primaryIndicator":"No","displayOrder":"2"},{"longName":"Specimen","conceptCode":"C19157","definition":"A part of a thing, or of several things, taken to demonstrate or to determine the character of the whole, e.g. a substance, or portion of material obtained for use in testing, examination, or study; particularly, a preparation of tissue or bodily fluid taken for examination or diagnosis.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Quality","conceptCode":"C25283","definition":"An essential and distinguishing attribute of something or someone; a degree or grade of excellence or worth.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"81E148E0-1D16-5FC8-E053-F662850AA355","latestVersionIndicator":"Yes","beginDate":"2019-02-14","endDate":null,"createdBy":"MORENOC","dateCreated":"2019-02-14","modifiedBy":"ONEDATA","dateModified":"2019-02-14","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"81E148E0-1D2F-5FC8-E053-F662850AA355","beginDate":"2019-02-14","endDate":null,"createdBy":"MORENOC","dateCreated":"2019-02-14","modifiedBy":"ONEDATA","dateModified":"2019-02-14","deletedIndicator":"No"},{"value":"4","valueDescription":"Good","ValueMeaning":{"publicId":"3206718","version":"1","preferredName":"Good","longName":"3206718","preferredDefinition":"Valuable or useful or agreeable or pleasing.\r\n","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Good","conceptCode":"C64975","definition":"Valuable or useful or agreeable or pleasing.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F200425-789A-686D-E040-BB89AD437AE3","latestVersionIndicator":"Yes","beginDate":"2011-03-23","endDate":null,"createdBy":"REEVESD","dateCreated":"2011-03-23","modifiedBy":"KUMMEROA","dateModified":"2023-01-11","changeDescription":null,"administrativeNotes":"2023.1.11 Alt VM Name added per ticket request CADSR0001837. ak","unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"81E148E0-1D39-5FC8-E053-F662850AA355","beginDate":"2019-02-14","endDate":null,"createdBy":"MORENOC","dateCreated":"2019-02-14","modifiedBy":"ONEDATA","dateModified":"2019-02-14","deletedIndicator":"No"},{"value":"5","valueDescription":"Best","ValueMeaning":{"publicId":"6643731","version":"1","preferredName":"Best","longName":"6643731","preferredDefinition":"Having the most positive qualities.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Best","conceptCode":"C25432","definition":"Having the most positive qualities.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"81E148E0-1D43-5FC8-E053-F662850AA355","latestVersionIndicator":"Yes","beginDate":"2019-02-14","endDate":null,"createdBy":"MORENOC","dateCreated":"2019-02-14","modifiedBy":"ONEDATA","dateModified":"2019-02-14","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"81E148E0-1D5C-5FC8-E053-F662850AA355","beginDate":"2019-02-14","endDate":null,"createdBy":"MORENOC","dateCreated":"2019-02-14","modifiedBy":"ONEDATA","dateModified":"2019-02-14","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"2524082","version":"1","preferredName":"Person Measure/Instrument Testing","preferredDefinition":"Process and results associated with self-reported measures and instruments, surveys, other tools","longName":"MEASURE/INSTRUMENT TESTING","context":"CCR","contextVersion":"1","origin":"CCR:Center for Cancer Research","workflowStatus":"RELEASED","registrationStatus":"Application","id":"1E838B40-6636-0A25-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-09-28","endDate":null,"createdBy":"REEVESD","dateCreated":"2006-09-28","modifiedBy":"REEVESD","dateModified":"2008-11-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"2452834","version":"1","preferredName":"Scale","preferredDefinition":"an ordered reference standard.","longName":"C25664","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Scale","conceptCode":"C25664","definition":"An ordered reference standard used to measure incremental changes.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Standard","id":"0D51E8D8-69DD-387C-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-02-24","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2006-02-24","modifiedBy":"ONEDATA","dateModified":"2006-02-24","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"Alliance Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"81E148E0-1CDA-5FC8-E053-F662850AA355","latestVersionIndicator":"Yes","beginDate":"2019-02-14","endDate":null,"createdBy":"MORENOC","dateCreated":"2019-02-14","modifiedBy":"MORENOC","dateModified":"2019-11-06","changeDescription":"11/6/2019: CM Released as part of draft content review","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[],"AlternateNames":[],"ReferenceDocuments":[{"name":"AML MRD Assay: Specimen Quali","type":"Preferred Question Text","description":"AML MRD Assay: Specimen Quality?","url":null,"context":"Alliance"}],"origin":"Alliance Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"81E19A48-F544-5D1F-E053-F662850ACDB6","latestVersionIndicator":"Yes","beginDate":"2019-02-14","endDate":null,"createdBy":"MORENOC","dateCreated":"2019-02-14","modifiedBy":"MORENOC","dateModified":"2019-11-06","changeDescription":"11/6/2018: CM Released as part of draft content review","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}